Health

N.Y. appoints geologist with ties to fracking

New York’s selection of a geologist with industry ties for a study on the potential link between hydraulic fracturing and earthquakes has both environmentalists and government watchdogs concerned, according to a Bloomberg article.

The state’s Department of Environmental Conservation chose Robert Jacobi, a University at Buffalo professor who has advised drillers for two decades, to lead the seismology study as part of its environmental review of hydraulic fracturing.

The controversial drilling ...

continue reading...

Prepare for doctor’s questions about incontinence

When you’re getting treatment for urinary incontinence, your doctor is likely to ask you a series of questions, according to the Mayo Clinic.

The clinic has compiled a list of those probable questions, so patients can be prepared for them and have their answers ready.

The Clinic acknowledges that urinary incontinence can be a troubling and inconvenient condition that obliges patients to make adjustments to their lifestyles in order to compensate for ...

continue reading...

J&J suppressed warnings about hip implant

A story in U.K. newspaper The Telegraph says Johnson & Johnson employees were not only aware of problems with its ASR hip implant for years before the device’s 2010 recall, but actively discussed manipulating data to conceal those problems.

Studies show that nearly half of the implants, made by Johnson & Johnson subsidiary DePuy Orthopaedics, break down and need replacement after only a few years. They also have a tendency to ...

continue reading...

Inspections shut down 11 Mass. pharmacies

State officials in Massachusetts have shut down 11 specialty pharmacies of the type responsible for last year’s deadly meningitis outbreak, following a series of surprise inspections.

According to a story in USA Today, inspectors looked in on 40 compounding pharmacies, which produce custom prescriptions in response to specific physician orders.

Compounding pharmacies aren’t subject to the same regulations as other pharmaceutical manufacturers.

That regulatory gap drew attention last year, ...

continue reading...

Merck delays approval for new drug

According to a story in the New York Times, Merck is delaying its attempts to get approval for an experimental osteoporosis drug called odanacatib, because it is seeking additional data from a clinical trial. That announcement helped send the company’s shares down 3 percent.

The story says Merck reported that it earned $1.4 billion, or 46 cents a share, in the fourth quarter. That compares with $1.51 billion, or 49 cents ...

continue reading...

Editorial: Hip implant maker has ‘explaining to do’

An editorial in the New York Times takes Johnson & Johnson subsidiary DePuy Orthopaedics to task for apparently sitting on evidence that a line of its hip implants posed a danger to patients.

“Though the company says the evidence will ultimately show that it acted appropriately, it clearly has a lot of explaining to do,” the editorial says.

The model in question ...

continue reading...
Page 40 of 120 «...1020303839404142...»